Early Detection of Cancer Through Blood Biomarkers

Detecting cancer at an early stage can greatly enhance the chances of recovery. Recent research from U.S. scientists indicates that blood biomarkers might be able to identify tumors more than three years before a formal diagnosis.

The innovation comes from tiny bits of genetic material that tumors release. If an effective method for analyzing these DNA signatures in blood can be implemented on a large scale, it might provide a dependable approach to catch cancer much sooner.

“Identifying cancer three years earlier gives us time for intervention,” says Yuxuan Wang, an oncology researcher at Johns Hopkins University in Maryland. “This early identification means tumors are likely to be less advanced and have better chances of being curable.”

The research team looked at blood samples from 26 participants within a broader health study, all of whom were diagnosed with cancer within six months after the samples were collected. These were compared to blood from another 26 individuals who did not develop cancer.

Essentially, the test focused on circulating tumor DNA, or ctDNA. By employing a combination of algorithms and cross-references, the researchers were able to identify genetic alterations associated with tumors, despite their rarity.

Out of the 52 participants in the study, the multi-cancer early detection (MCED) test flagged cancer in eight individuals—indicating that nearly 31 percent of those who developed cancer were detected through blood analysis.

For six of those eight patients, samples from 3.1 to 3.5 years earlier were accessible, and cancer was detectable in four of them. Remarkably, the same DNA fragments linked to tumors had started to emerge, even at concentrations nearly 80 times lower than those identified by the MCED test.

However, there remains significant work ahead. As samples are analyzed further back in time, the levels of detectable ctDNA become lower. For cancer to be identified years in advance, more sensitive blood tests will need to be developed.

“This study highlights the potential of MCED tests to detect cancers very early, establishing the sensitivity benchmarks necessary for their success,” notes Bert Vogelstein, an oncology researcher at the Ludwig Center at Johns Hopkins.

Scientists are making impressive strides in pinpointing ways to detect cancer earlier, particularly via blood tests. Still, navigating through trials and gaining regulatory approval can be quite challenging.

Despite these obstacles, optimism abounds: each new study contributes to our understanding of how cancer initiates and can be identified at earlier stages.

Moreover, advances in treatment options—such as therapies that can target multiple cancer types—offer further hope for improving survival rates.

“Detecting cancer years before clinical diagnosis could lead to better management and outcomes,” asserts Nickolas Papadopoulos, an oncology researcher at the Ludwig Center. “We, of course, need to figure out the right clinical follow-up after a positive test for such cancers.”

The findings from this research were published in Cancer Discovery.